UNSPSC 51391710: Cimaterol

This classification denotes a beta-adrenergic agonist with the molecular formula C12H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZPY8VRF0GB, chemically known as benzonitrile, 2-amino-5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (+-)- but generally known as cimaterol, which bears US NIH Compound Identifier 2755. European Medicines Agency schedules Cimaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06276MIG.

UNSPSC 51391710 Cimaterol is a Commodity code that covers pharmaceutical products, though recent state and local solicitations show actual procurement focused on naloxone (opioid reversal medication) and drug deactivation systems rather than cimaterol specifically. Seminole County, Florida and the Texas Health and Human Services Commission are the primary issuing bodies active under this code in the recent record. Seminole County's procurement spans health-department operations at the county level, while the Texas HHS Commission operates at the state level with broader pharmacy benefit administration scope. The work being solicited includes supply and delivery of naloxone units and safe drug deactivation systems for community health support, as well as vendor assessment for direct-to-manufacturer prescription fulfillment programs that operate outside traditional pharmacy benefit manager and wholesaler channels. Neither solicitation specifies set-aside or disadvantaged-enterprise preferences.

Seminole County, Florida and Texas represent the geographic concentration in recent activity. Seminole County issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (note: date discrepancy in source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; the contract carries an initial two-year term with a one-year renewal option and is potentially funded through FEMA. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, with the same response deadline, to gather vendor capabilities for implementing a direct-to-manufacturer prescription program for self-insured employer and state agency health plans, moving prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization relationships. Both solicitations emphasize compliance with federal and state regulations, and neither identifies a specific budget range at the time of posting.